Smart Innovation
Antimicrobial resistance (AMR)
AMR develops when bacteria, fungi or viruses are exposed to antibiotics, antifungals or antivirals. As a result, the antimicrobials become ineffective and infections may persist. In addition, medical interventions including surgery, chemotherapy and stem cell therapy may become impossible.
AMR is considered the biggest global threat of Health and Food Safety.
AMR Insights
For Researchers and Entrepreneurs who wish to investigate, develop and commercialize novel vaccines, diagnostics and antimicrobials to prevent Antimicrobial resistance, AMR Insights offers selected, global information and data, specific education and extensive networking and partnering opportunities.
AMR Insights is for:
- Researchers at Universities and University Medical Centers
- Researchers at Research Institutes
- R&D professionals in Pharma, Biopharma and Diagnostics companies
- Entrepreneurs in start-up’s and spin off companies
- Innovators, Venture Capitalists.
Latest Topics
-
10 October 2025The Emerging Resistance Index: tracking early resistance to new antibiotics
A new study introduces the Emerging Resistance Index (ERI) — a quantitative tool designed to monitor how quickly resistance develops to newly approved antibiotics. The ERI integrates multiple parameters, including pooled AMR proportions and trends, the presence of resistance and antibiotic use surveillance systems, the time between drug approval and resistance detection, and the frequency […]
Read more... -
08 October 2025Winners Announced for the 2025 Vivli AMR Surveillance Data Challenge, funded by Johnson & Johnson, Paratek, Pfizer, and NIH
The 2025 Vivli AMR Surveillance Data Challenge, funded by Johnson & Johnson, Paratek, Pfizer, and the U.S. NIH, attracted 58 teams from 22 countries to develop innovative analyses of global AMR surveillance datasets. Two Grand Prizes were awarded: one to George Priya Doss Chandrakumar’s team for revealing how air pollution may drive fluconazole resistance in […]
Read more... -
06 October 2025Discovery and artificial intelligence-guided mechanistic elucidation of a narrow-spectrum antibiotic
A large-scale screening of 10,747 bioactive molecules led to the discovery of enterololin, a novel antibacterial compound with narrow-spectrum activity specifically targeting Enterobacteriaceae such as E. coli, including adherent-invasive E. coli (AIEC) linked to inflammatory bowel disease. When combined with the polymyxin analogue SPR741, enterololin overcomes bacterial resistance by disrupting lipoprotein trafficking via the LolCDE […]
Read more...
More news related to Smart innovation
